Ashley Cordova's Insider Trades & SAST Disclosures
Ashley Cordova's most recent trade in NovoCure Ltd was a trade of 224,123 Stock Options (Right to buy) done . Disclosure was reported to the exchange on March 4, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Ashley Cordova.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| NovoCure Ltd | Ashley Cordova | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 224,123 | 224,123 | - | - | Stock Options (Right to buy) | |
| NovoCure Ltd | Ashley Cordova | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 18.19 per share. | 04 Mar 2025 | 151,181 | 355,186 (0%) | 0% | 18.2 | 2,749,982 | Ordinary Shares |
| NovoCure Ltd | Ashley Cordova | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 18.54 per share. | 03 Mar 2025 | 2,053 | 204,005 (0%) | 0% | 18.5 | 38,055 | Ordinary Shares |
| NovoCure Ltd | Ashley Cordova | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 19.92 per share. | 27 Feb 2025 | 9,345 | 210,207 (0%) | 0% | 19.9 | 186,170 | Ordinary Shares |
| NovoCure Ltd | Ashley Cordova | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 18.28 per share. | 27 Feb 2025 | 2,341 | 206,058 (0%) | 0% | 18.3 | 42,804 | Ordinary Shares |
| NovoCure Ltd | Ashley Cordova | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 20.55 per share. | 27 Feb 2025 | 1,808 | 208,399 (0%) | 0% | 20.5 | 37,153 | Ordinary Shares |
| NovoCure Ltd | Ashley Cordova | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 14.75 per share. | 31 Dec 2024 | 373 | 219,552 (0%) | 0% | 14.7 | 5,501 | Ordinary Shares |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 20.14 per share. | 02 Aug 2024 | 688 | 219,179 (0%) | 0% | 20.1 | 13,857 | Ordinary Shares |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 12.24 per share. | 28 Jun 2024 | 1,286 | 220,465 (0%) | 0% | 12.2 | 15,741 | Ordinary Shares |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 156,348 | 156,348 | - | - | Stock Options (Right to buy) | |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 16.30 per share. | 27 Feb 2024 | 102,249 | 219,867 (0%) | 0% | 16.3 | 1,666,659 | Ordinary Shares |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.15 per share. | 31 Oct 2023 | 7,752 | 117,443 (0%) | 0% | 7.2 | 55,427 | Ordinary Shares |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2023 | 7,752 | 0 | - | - | Stock Option (Right to Buy) | |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.46 per share. | 31 Oct 2023 | 7,561 | 107,211 (0%) | 0% | 11.5 | 86,649 | Ordinary Shares |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2023 | 7,561 | 175 | - | - | Stock Option (Right to Buy) | |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.44 per share. | 31 Oct 2023 | 2,480 | 109,691 (0%) | 0% | 11.4 | 28,371 | Ordinary Shares |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2023 | 2,480 | 0 | - | - | Stock Option (Right to Buy) | |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.46 per share. | 31 Oct 2023 | 175 | 117,618 (0%) | 0% | 11.5 | 2,006 | Ordinary Shares |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2023 | 175 | 0 | - | - | Stock Option (Right to Buy) | |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 21.82 per share. | 01 Sep 2023 | 883 | 99,650 (0%) | 0% | 21.8 | 19,265 | Ordinary Shares |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 30.25 per share. | 02 Aug 2023 | 1,144 | 100,533 (0%) | 0% | 30.3 | 34,607 | Ordinary Shares |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 35.28 per share. | 30 Jun 2023 | 367 | 101,677 (0%) | 0% | 35.3 | 12,948 | Ordinary Shares |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 76.16 per share. | 03 Mar 2023 | 4,730 | 102,085 (0%) | 0% | 76.2 | 360,234 | Ordinary Shares |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 76.16 per share. | 03 Mar 2023 | 775 | 101,310 (0%) | 0% | 76.2 | 59,024 | Ordinary Shares |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 11,808 | 106,815 (0%) | 0% | 0 | Ordinary Shares | |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 75.28 per share. | 02 Mar 2023 | 1,055 | 95,007 (0%) | 0% | 75.3 | 79,418 | Ordinary Shares |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2023 | 39,614 | 39,614 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2023 | 23,818 | 98,260 (0%) | 0% | 0 | Ordinary Shares | |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 76.36 per share. | 28 Feb 2023 | 2,198 | 96,062 (0%) | 0% | 76.4 | 167,845 | Ordinary Shares |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 62.30 per share. | 06 Jan 2023 | 66 | 74,442 (0%) | 0% | 62.3 | 4,112 | Ordinary Shares |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2022 | 2,000 | 7,752 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.15 per share. | 02 Dec 2022 | 2,000 | 74,376 (0%) | 0% | 7.2 | 14,300 | Ordinary Shares |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 79.04 per share. | 02 Sep 2022 | 885 | 72,376 (0%) | 0% | 79.0 | 69,948 | Ordinary Shares |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 70.20 per share. | 02 Aug 2022 | 7,122 | 73,261 (0%) | 0% | 70.2 | 499,964 | Ordinary Shares |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 59.08 per share. | 05 Jul 2022 | 251 | 66,139 (0%) | 0% | 59.1 | 14,828 | Ordinary Shares |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 70.10 per share. | 08 Mar 2022 | 759 | 60,848 (0%) | 0% | 70.1 | 53,206 | Ordinary Shares |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 37,664 | 37,664 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 21,508 | 63,312 (0%) | 0% | 0 | Ordinary Shares | |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 5,140 | 5,140 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.60 per share. | 03 Mar 2022 | 3,840 | 64,688 (0%) | 0% | 15.6 | 59,904 | Ordinary Shares |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2022 | 3,840 | 0 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2022 | 1,200 | 7,736 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.46 per share. | 03 Mar 2022 | 1,200 | 65,888 (0%) | 0% | 11.5 | 13,752 | Ordinary Shares |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 74.50 per share. | 03 Mar 2022 | 1,149 | 62,163 (0%) | 0% | 74.5 | 85,598 | Ordinary Shares |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 70.41 per share. | 03 Mar 2022 | 556 | 61,607 (0%) | 0% | 70.4 | 39,146 | Ordinary Shares |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 63.83 per share. | 06 Jan 2022 | 46 | 41,804 (0%) | 0% | 63.8 | 2,936 | Ordinary Shares |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 107.28 per share. | 02 Nov 2021 | 209 | 41,758 (0%) | 0% | 107.3 | 22,421 | Ordinary Shares |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 138.23 per share. | 02 Sep 2021 | 828 | 41,967 (0%) | 0% | 138.2 | 114,456 | Ordinary Shares |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Aug 2021 | 10,000 | 3,840 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.60 per share. | 12 Aug 2021 | 10,000 | 45,993 (0%) | 0% | 15.6 | 156,000 | Ordinary Shares |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.50 per share. | 12 Aug 2021 | 8,026 | 54,019 (0%) | 0% | 21.5 | 172,559 | Ordinary Shares |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Aug 2021 | 8,026 | 3,297 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 140.90 per share. | 12 Aug 2021 | 8,026 | 45,993 (0%) | 0% | 140.9 | 1,130,879 | Ordinary Shares |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Aug 2021 | 7,298 | 5,172 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 140.90 per share. | 12 Aug 2021 | 7,298 | 45,993 (0%) | 0% | 140.9 | 1,028,288 | Ordinary Shares |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 47.04 per share. | 12 Aug 2021 | 7,298 | 53,291 (0%) | 0% | 47.0 | 343,298 | Ordinary Shares |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Aug 2021 | 5,927 | 0 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 141.06 per share. | 12 Aug 2021 | 5,927 | 45,993 (0%) | 0% | 141.1 | 836,063 | Ordinary Shares |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.25 per share. | 12 Aug 2021 | 5,927 | 51,920 (0%) | 0% | 19.3 | 114,095 | Ordinary Shares |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Aug 2021 | 2,767 | 5,533 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 140.90 per share. | 12 Aug 2021 | 2,767 | 45,993 (0%) | 0% | 140.9 | 389,870 | Ordinary Shares |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 32.02 per share. | 12 Aug 2021 | 2,767 | 48,760 (0%) | 0% | 32.0 | 88,599 | Ordinary Shares |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Aug 2021 | 2,606 | 6,375 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 140.90 per share. | 12 Aug 2021 | 2,606 | 45,993 (0%) | 0% | 140.9 | 367,185 | Ordinary Shares |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 69.37 per share. | 12 Aug 2021 | 2,606 | 48,599 (0%) | 0% | 69.4 | 180,778 | Ordinary Shares |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 12 Aug 2021 | 1,733 | 44,260 (0%) | 0% | 0 | Ordinary Shares | |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 137.12 per share. | 06 Jul 2021 | 100 | 35,993 (0%) | 0% | 137.1 | 13,712 | Ordinary Shares |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 130.81 per share. | 08 Mar 2021 | 765 | 35,893 | - | 130.8 | 100,067 | Restricted Share Units |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 04 Mar 2021 | 910 | 36,658 (0%) | 0% | 0 | Ordinary Shares | |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 137.55 per share. | 04 Mar 2021 | 567 | 37,568 | - | 137.6 | 77,993 | Restricted Share Units |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2021 | 20,004 | 20,004 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2021 | 10,886 | 38,135 | - | 0 | Restricted Share Units | |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 152.05 per share. | 02 Mar 2021 | 428 | 27,249 | - | 152.1 | 65,079 | Restricted Share Units |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 149.10 per share. | 27 Feb 2021 | 1,465 | 27,677 (0%) | 0% | 149.1 | 218,432 | Ordinary Shares |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2021 | 1,465 | 0 | - | - | Restricted Stock Units | |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 117.41 per share. | 02 Nov 2020 | 230 | 26,212 (0%) | 0% | 117.4 | 27,005 | Ordinary Shares |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2020 | 11,336 | 11,336 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | Ashley Cordova | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2020 | 5,904 | 26,442 | - | 0 | Restricted Share Units |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges